Nkarta disclosed initial human data for its NK-cell therapy program in two autoimmune diseases, reporting safety and signs of efficacy. The company plans to share first clinical data for myositis and systemic sclerosis at the American College of Rheumatology meeting. For the autoimmune cell-therapy space, early safety plus efficacy signals can catalyze follow-on funding and partnerships—especially as developers seek repeatable strategies to reset immune pathways without the manufacturing and durability concerns seen in some other modalities.